Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: An observational study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 13 09 2019
accepted: 27 02 2020
entrez: 26 3 2020
pubmed: 26 3 2020
medline: 27 6 2020
Statut: epublish

Résumé

Given the complicated history of Japan's National Immunization Program, a significant proportion of Japanese people including healthcare workers (HCWs) still lack adequate immunity against measles, mumps, and rubella (MMR), resulting in occasional outbreaks. In 2014, the Japanese Society of Infection Prevention and Control (JSIPC) published vaccination guidelines for HCWs. We evaluated antibody titers before and after MMR vaccination in HCWs at the Nara Medical University Hospital, the attainment rate of the target antibody titers defined by the JSIPC guidelines, and the safety of vaccines. We measured MMR antibody titers in HCWs, followed by inoculation with the respective monovalent vaccines and/or trivalent MMR (tMMR) vaccine according to the JSIPC guidelines. Among 467 HCWs evaluated, antibody titers against measles and mumps measured using the IgG-enzyme immunoassay increased from 11.0 [interquartile range (IQR): 8.0-13.6] to 13.7 (IQR: 11.3-16.9; P < 0.001) and from 2.8 (IQR: 2.1-3.5) to 4.8 (IQR: 3.7-5.7; P < 0.001), respectively. By evaluating a logarithmic value of log2(X + 1) converted from an antibody titer X, antibody titers against rubella measured using the hemagglutination assay increased from 3.2 (IQR: 0-4.1) to 6.0 (IQR: 4.6-8.0; P < 0.001). Antibody titer elevated following tMMR vaccination was lower than that following monovalent vaccination in a single dose of the measles-containing, a single dose of the mumps-containing, and two doses of rubella-containing vaccine groups (P = 0.01, 0.01, and <0.001, respectively). After vaccination, 20.0%, 61.5%, and 46.2% of HCWs attained target antibody titers specified by the JSIPC guidelines for measles, rubella, and mumps, respectively. The systemic response in female HCWs who underwent monovalent mumps vaccination was statistically higher than that in others. Although the vaccination program for HCWs according to the JSIPC guidelines caused increased MMR antibody titers, the rates of attaining the target criteria were low.

Identifiants

pubmed: 32208432
doi: 10.1371/journal.pone.0230329
pii: PONE-D-19-25746
pmc: PMC7092999
doi:

Substances chimiques

Antibodies, Viral 0
Measles-Mumps-Rubella Vaccine 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0230329

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Infect Dis. 2016 Dec 15;214(12):1980-1986
pubmed: 27923955
J Infect Chemother. 2013 Oct;19(5):787-98
pubmed: 23835871
J Clin Virol. 2015 Aug;69:214-8
pubmed: 26209410
Vaccine. 2005 Sep 30;23(41):4921-5
pubmed: 15996797
Clin Vaccine Immunol. 2012 Nov;19(11):1810-7
pubmed: 22971778
Clin Infect Dis. 2015 May 15;60(10):e58-65
pubmed: 25637587
J Infect Chemother. 2019 Jan;25(1):78-81
pubmed: 30064948
Tohoku J Exp Med. 2014;234(2):111-6
pubmed: 25224029
J Med Virol. 2000 Dec;62(4):511-7
pubmed: 11074481
Hawaii J Med Public Health. 2014 Dec;73(12):376-81
pubmed: 25628969
Lancet. 2014 Apr 26;383(9927):1460-1461
pubmed: 24766958
Western Pac Surveill Response J. 2018 Jun 30;9(2):26-33
pubmed: 30057855
Kansenshogaku Zasshi. 2016 Jul;90(4):518-9
pubmed: 30212042
Science. 1997 Jun 27;276(5321):2024-7
pubmed: 9197261
Virology. 2000 Jun 20;272(1):98-105
pubmed: 10873752
Travel Med Infect Dis. 2018 Sep - Oct;25:8-9
pubmed: 30176282
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313

Auteurs

Taku Ogawa (T)

Center for Infectious Diseases, Nara Medical University, Nara, Japan.

Takashi Inoue (T)

Institute for Clinical and Translational Science, Nara Medical University, Nara, Japan.

Kei Kasahara (K)

Center for Infectious Diseases, Nara Medical University, Nara, Japan.

Mitsuru Konishi (M)

Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Center for Health Control, Nara Medical University, Nara, Japan.

Keiichi Mikasa (K)

Center for Infectious Diseases, Nara Medical University, Nara, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH